Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
News SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate and vilanterol inhalation powder, a generic version of Breo® Ellipta®1 100/25, has been accepted for filing by the U.S. […]